Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.76
- Piotroski Score 2.00
- Grade Buy
- Symbol (ADAG)
- Company Adagene Inc.
- Price $3.05
- Changes Percentage (1.33%)
- Change $0.04
- Day Low $2.98
- Day High $3.14
- Year High $4.38
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $5.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.44
- Trailing P/E Ratio -6.77
- Forward P/E Ratio -6.77
- P/E Growth -6.77
- Net Income $-18,946,370
Income Statement
Quarterly
Annual
Latest News of ADAG
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The model makers in Madagascar bring history's long-lost ships back to life
A workshop in Madagascar is meticulously crafting a replica of a 17th-century French trading ship that sank with treasure. Le Village model ship making company recreates historic vessels with attentio...
By AP NEWS | 1 month ago -
Adagene First Half 2024 Earnings: US$0.39 loss per share (vs US$0.094 loss in 1H 2023)
The company reported a net loss of US$17.0m, widening by 314% from the previous period, with a loss per share of US$0.39. Revenue is forecasted to grow 55% annually for the next 3 years, outperforming...
By Yahoo! Finance | 3 months ago -
Adagene Inc. (NASDAQ:ADAG) most popular amongst private equity firms who own 39% of the shares, institutions hold 30%
The ownership structure of Adagene Inc. reveals private equity firms as major shareholders at 39%, followed by institutions at 30%. CEO and top 5 shareholders collectively control a significant portio...
By Yahoo! Finance | 4 months ago
